American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Jan 15, 2021 Supporting Materials Title: A Phase 2b, Open-label, Single-arm Study of Zanidatamab (ZW25) Monotherapy in Patients with Advanced or Metastatic HER2-amplified Biliary Tract Cancer (BTC): HERIZON-BTC-01 Study 410.1 KB Title: Zanidatamab (ZW25) in HER2-positive Biliary Tract Cancer (BTC): Results From a Phase 1 Study 390.9 KB Title: Zanidatamab (ZW25) in HER2-expressing Gastroesophageal Adenocarcinoma (GEA): Results from a Phase 1 Study 1.8 MB
Title: A Phase 2b, Open-label, Single-arm Study of Zanidatamab (ZW25) Monotherapy in Patients with Advanced or Metastatic HER2-amplified Biliary Tract Cancer (BTC): HERIZON-BTC-01 Study 410.1 KB
Title: Zanidatamab (ZW25) in HER2-positive Biliary Tract Cancer (BTC): Results From a Phase 1 Study 390.9 KB
Title: Zanidatamab (ZW25) in HER2-expressing Gastroesophageal Adenocarcinoma (GEA): Results from a Phase 1 Study 1.8 MB
